|
Single agent vanucizumab (RO5520985) for platinum (Pt)-resistant recurrent ovarian cancer (OC): Results from a single arm extension phase of the phase I FIH study. |
|
|
Consulting or Advisory Role - AstraZeneca; Roche Pharma AG |
|
|
Consulting or Advisory Role - MSD Oncology; Roche Pharma AG |
Travel, Accommodations, Expenses - GlaxoSmithKline; MSD; Roche Pharma AG |
|
|
No Relationships to Disclose |
|
Isabelle Laure Ray-Coquard |
Research Funding - PharmaMar (Inst); Roche Pharma AG (Inst) |
Travel, Accommodations, Expenses - AstraZeneca; Novartis; Roche Pharma AG |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Employment - Roche Pharma AG |
Stock and Other Ownership Interests - Roche Pharma AG |
Patents, Royalties, Other Intellectual Property - Roche |
|
|
Employment - Roche Pharma AG |
|
|
Employment - Roche Pharma AG |
|
|
Employment - Roche Pharma AG |
|
|
Employment - Roche Pharma AG |
|
|
Employment - Roche Pharma AG |
|
|
Employment - Roche Pharma AG |
|
|
Employment - Roche Pharma AG |
Stock and Other Ownership Interests - Roche Pharma AG |
|
|
Consulting or Advisory Role - Roche Pharma AG |
Research Funding - Roche Pharma AG (Inst) |